Key Takeaways
- • Morningstar downgraded CVC Capital Partners (CVC.AS) from buy to hold on May 21, 2026, citing underperformance and uncertainty around carried interest outlook, with fair value cut by 20%.
- • Price target reduced to €14.50 from a higher prior level, reflecting reassessed valuation following mixed performance results and near-term earnings guidance cuts.
- • CVC stock traded at €13.04 on May 22, 2026, down 8.81% year-to-date despite a +1.24% one-day gain, signaling investor concerns over performance-related earnings trajectory.
- • Performance fees are expected to account for nearly all earnings growth over the next three years, creating lumpy returns and earnings visibility challenges for the private equity manager.
- • Downgrade comes amid concurrent M&A activity: CVC and Groupe Bruxelles Lambert (GBL) launched a €10.7 billion takeover bid for Italian pharmaceutical company Recordati at €51.29 per share.
Summary
Morningstar downgraded CVC Capital Partners to hold from buy on May 21, 2026, reducing its price target to €14.50 as the research firm reassessed the private equity group's valuation following concerns over underperformance and carried interest visibility. The 20% fair value cut reflects deteriorating near-term earnings guidance, with Morningstar noting that performance-related fees—expected to drive nearly all earnings growth over the next three years—remain dependent on initial returns from key funds, creating significant earnings lumpiness.
CVC's stock price reflected the headwinds, trading at €13.04 on May 22, 2026, down 8.81% year-to-date despite a modest 1.24% daily gain. The downgrade stands in contrast to broader analyst sentiment; according to consensus data, 7 out of 10 analysts maintain buy ratings, with only 3 recommending holds and none rating the stock a sell. This suggests Morningstar's more cautious stance represents a minority view within the analyst community, though it highlights material concerns about the firm's near-term performance trajectory and earnings quality.
The timing of the downgrade coincides with CVC's announcement of a significant investment opportunity. On May 22, 2026—one day after the Morningstar downgrade—CVC and Groupe Bruxelles Lambert launched a joint €10.7 billion full takeover offer for Italy's Recordati pharmaceutical company at €51.29 per share. This deal activity underscores CVC's continued deployment capacity despite the valuation concerns raised by Morningstar, suggesting the firm maintains sufficient dry powder and investor backing to pursue large-scale platform acquisitions, even as public market concerns mount over realized returns and carried interest realization timelines.
CVC's stock price reflected the headwinds, trading at €13.04 on May 22, 2026, down 8.81% year-to-date despite a modest 1.24% daily gain. The downgrade stands in contrast to broader analyst sentiment; according to consensus data, 7 out of 10 analysts maintain buy ratings, with only 3 recommending holds and none rating the stock a sell. This suggests Morningstar's more cautious stance represents a minority view within the analyst community, though it highlights material concerns about the firm's near-term performance trajectory and earnings quality.
The timing of the downgrade coincides with CVC's announcement of a significant investment opportunity. On May 22, 2026—one day after the Morningstar downgrade—CVC and Groupe Bruxelles Lambert launched a joint €10.7 billion full takeover offer for Italy's Recordati pharmaceutical company at €51.29 per share. This deal activity underscores CVC's continued deployment capacity despite the valuation concerns raised by Morningstar, suggesting the firm maintains sufficient dry powder and investor backing to pursue large-scale platform acquisitions, even as public market concerns mount over realized returns and carried interest realization timelines.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.